Global Antimicrobial Susceptibility Testing Market By Product (Manual, Automated), By Type (Antibacterial, Antifungal), Application (Clinical Diagnostics, Epidemiology), By Method (ETEST, Disk Diffusion), By End-User (Diagnostic Centers and Hospitals, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Research and Academic Institutes), By Region, Industry Analysis, Share, Growth, Trends, and Forecast, 2021-2028

Covid-19 Impact on Global Antimicrobial Susceptibility Testing Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC21

No. of Pages : 350

The global antimicrobial susceptibility testing market is expected to grow from USD 3.3 billion in 2020 to USD 5.1 million by 2028 at a CAGR of 5.6% over the forecast period 2021-2028.

Market Overview:

Antimicrobial susceptibility testing is employed to detect which antimicrobials will inhibit the expansion of the bacteria or fungi, causing an infection. This test's obtained results l help a healthcare practitioner determine which drugs are likely to be best in treating an individual's infection. Increased funding, research grants and public-private investments, technological advancements towards rapid testing methods are supposed to fuel the expansion of the antimicrobial susceptibility testing market. Also, the increasing prevalence of infections due to bacterial pathogens and overuse of antibiotics─ which results in antibiotic resistance in bacterial organisms; development of higher standards for fungal susceptibility, and therefore the increasing use of rapid commercial AST systems for fungal testing are the key factors supporting the expansion of the market.

Market Dynamics:

Drivers:

Increasing growth opportunities because of Cleanroom technology

An increase in bacterial pathogen infection cases

Restraints:

High cost associated with antimicrobial susceptibility testing

Key Market Players:

bioMérieux SA, Danaher, BD, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Liofilchem S.r.l., Accelerate Diagnostics, Inc., Alifax S.r.l., Creative Diagnostics., Merck KGaA, Synbiosis, and Zhuhai DL Biotech Co are some of the prominent players in the global antimicrobial susceptibility testing market.

The market is segmented based on the below-mentioned segments:

On the Basis of Product: Revenue

o Manual

o Automated

On the Basis of Type: Revenue

o Antibacterial

o Antifungal

On the Basis of Application: Revenue

o Clinical Diagnostics

o Epidemiology

On the Basis of End-User: Revenue

o Diagnostic Centers & Hospitals

o Pharmaceutical & Biotechnology Companies

o Contract Research Organizations (CROs)

o Research & Academic Institutes

On The Basis of Region: Revenue

North America

- U.S.A
- Canada
- Mexico

Europe

Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

Asia Pacific

- China
- Japan
- India
- SEA
- Australia
- Rest Of APAC

South America

- Brazil
- Argentina
- Rest of South America

Middle East & Africa

- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Report Description

Year Consideration
- Base year – 2020
- Historic Year-2017-2019
- Forecast year- 2021 to 2028

The global antimicrobial susceptibility testing market will be based on revenue and volume. The study covers the market share for segments, countries, regions, and players.

The regions evaluated for the global antimicrobial susceptibility testing market are Europe, North America, Asia Pacific, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country-level.

The report provides an in-depth pricing analysis, value chain analysis, industry road map, and micro and macro factors.

The research report further provides the attractiveness of antimicrobial susceptibility testing and regions based on their growth rate (CAGR), market size, and attractiveness by analyzing present and future prospects to analyze market growth and development in the future.

Also, the study focuses on market-related driving forces, restraints, potential opportunities for the market, significant developments, and advancement that serve as a key potential for investors.

The study offers an extensive evaluation of Porter's five forces analysis, SWOT analysis, and PESTEL analysis to provide data and information related to the business.

Porter's five forces model is analyzed to understand the overall competitive scenario that prevails in the market. The SWOT analysis also identifies the positive as well as the negative characteristics of market development which influences the company’s growth and development to sustain and survive in the long run. The PESTEL analysis identifies the macro (external) forces affecting the organization.

The report includes a thorough analysis of the company profiles of major companies operating in the global antimicrobial susceptibility testing market and a comparative evaluation based on their business overviews, product offering, geographic presence, market share, business strategy, recent developments, product development & innovations, joint ventures, partnerships, mergers & acquisitions, expansions, SWOT analysis, and key financial information. It helps in evaluating the overall competition present in the market scenario.

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Full Name

Company Name

Designation/Position

Contact

Region/Country

Message

Kindly share your specific requirement (if any), so we can get back to you with a solution

TABLE OF CONTENTS
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE
1.4. MARKET DEFINITION
1.5. CURRENCY CONSIDERATION
1.6. YEAR CONSIDERATION
2. RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION
3. EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4. PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS
4.5. MARKET ATTRACTIVENESS ANALYSIS
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS
4.5.1.1. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY TYPE
4.5.1.2. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY APPLICATION
4.5.1.3. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY PRODUCT
4.5.1.4. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY END-USE
4.5.2. MARKET ATTRACTIVENESS BY REGION
4.5.2.1. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3. PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS
4.9. YEAR ON YEAR GROWTH RATE OF ANTIMICROBIAL SUSCEPTIBILITY TESTING
4.10. LIST OF SUPPLIERS
4.11. LIST OF BUYERS
4.12. COUNTRY LEVEL ANALYSIS
4.13. RULES AND REGULATION
5. MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. INCREASING GROWTH OPPORTUNITIES BECAUSE OF CLEANROOM TECHNOLOGY
5.1.2. AN INCREASE IN BACTERIAL PATHOGEN INFECTION CASES
5.2. MARKET RESTRAINTS
5.2.1. HIGH COST ASSOCIATED WITH ANTIMICROBIAL SUSCEPTIBILITY TESTING
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY APPLICATION - 2017-2028
6.1. KEY FINDINGS
6.2. CLINICAL DIAGNOSTICS
6.3. EPIDEMIOLOGY
7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY TYPE - 2017-2028
7.1. KEY FINDINGS
7.2. ANTIBACTERIAL
7.3. ANTIFUNGAL
8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY PRODUCT - 2017-2028
8.1. KEY FINDINGS
8.2. MANUAL
8.3. AUTOMATED
9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY END-USE- 2017-2028
9.1. KEY FINDINGS
9.2. DIAGNOSTIC CENTERS & HOSPITALS
9.3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4. CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.5. RESEARCH & ACADEMIC INSTITUTES
10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
10.1. KEY FINDINGS
10.2. NORTH AMERICA
10.3. EUROPE
10.4. ASIA PACIFIC
10.5. SOUTH AMERICA
10.6. MIDDLE EAST & AFRICA
11. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY
11.1.1. U.S.
11.1.2. CANADA
11.1.3. MEXICO
12. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY
12.1.1. GERMANY
12.1.2. U.K.
12.1.3. FRANCE
12.1.4. ITALY
12.1.5. SPAIN
12.1.6. SWEDEN
12.1.7. BELGIUM
12.1.8. TURKEY
12.1.9. RUSSIA
12.1.10. POLAND
12.1.11. SWITZERLAND
12.1.12. NETHERLANDS
12.1.13. REST OF EUROPE
13. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY
13.1.1.1. JAPAN
13.1.1.2. CHINA
13.1.1.3. INDIA
13.1.1.4. AUSTRALIA
13.1.1.5. SOUTH KOREA
13.1.1.6. MALAYSIA
13.1.1.7. INDONESIA
13.1.1.8. VIETNAM
13.1.1.9. NEW ZEALAND
13.1.1.10. PHILIPPINES
13.1.1.11. TAIWAN
13.1.1.12. SINGAPORE
13.1.1.13. REST OF ASIA-PACIFIC
14. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY
14.1.1.1. BRAZIL
14.1.1.2. ARGENTINA
14.1.1.3. CHILE
14.1.1.4. COLOMBIA
14.1.1.5. REST OF SOUTH AMERICA
15. MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
15.1. BY COUNTRY
15.1.1.1. SOUTH AFRICA
15.1.1.2. U.A.E.
15.1.1.3. SAUDI ARABIA
15.1.1.4. REST OF MIDDLE EAST AND AFRICA
16. COMPETITIVE LANDSCAPE
16.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
16.1.1. GLOBAL MARKET SHARE ANALYSIS
16.1.2. NORTH AMERICA MARKET SHARE ANALYSIS
16.1.3. EUROPE MARKET SHARE ANALYSIS
16.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS
16.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
16.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
16.2. LEADERSHIP MAPPING
16.2.1. VISIONARY PLAYERS
16.2.2. INNOVATORS PLAYERS
16.2.3. DYNAMIC DIFFERENTIATORS
16.2.4. EMERGING COMPANIES
16.3. COMPETITIVE SCENARIO AND TRENDS
16.3.1. MERGERS & ACQUISITIONS
16.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
16.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
16.3.4. EXPANSIONS
17. COMPANY PROFILES
17.1.1. BIOMÉRIEUX SA
17.1.1.1. COMPANY OVERVIEW
17.1.1.2. COMPANY SNAPSHOT
17.1.1.3. FINANCIAL ANALYSIS
17.1.1.3.1. REVENUE ANALYSIS
17.1.1.3.2. SALES ANALYSIS
17.1.1.3.3. PRICE ANALYSIS
17.1.1.3.4. MARGIN ANALYSIS
17.1.1.4. GEOGRAPHICAL PRESENCE
17.1.1.4.1. NORTH AMERICA
17.1.1.4.2. EUROPE
17.1.1.4.3. ASIA PACIFIC
17.1.1.4.4. SOUTH AMERICA
17.1.1.4.5. MIDDLE EAST & AFRICA
17.1.1.5. PRODUCT PORTFOLIO
17.1.1.6. SWOT ANALYSIS
17.1.1.7. RECENT DEVELOPMENT
17.1.2. DANAHER
17.1.3. BD
17.1.4. THERMO FISHER SCIENTIFIC INC.
17.1.5. BIO-RAD LABORATORIES, INC.
17.1.6. LIOFILCHEMS.R.L.
17.1.7. ACCELERATE DIAGNOSTICS, INC.
17.1.8. ALIFAXS.R.L.
17.1.9. CREATIVE DIAGNOSTICS.
17.1.10. MERCK KGAA
17.1.11. SYNBIOSIS
17.1.12. ZHUHAI DL BIOTECH CO
18. STRATEGIC RECOMMENDATIONS
LIST OF TABLE
1. RESEARCH ASSUMPTION
2. COVID-19 IMPACT ON MARKET
3. MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
5. GLOBAL CLINICAL DIAGNOSTICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6. GLOBAL EPIDEMIOLOGY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
8. GLOBAL ANTIBACTERIAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9. GLOBAL ANTIFUNGAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
11. GLOBAL MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
12. GLOBAL AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
14. GLOBAL DIAGNOSTIC CENTERS & HOSPITALS ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
15. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
16. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
17. GLOBAL RESEARCH & ACADEMIC INSTITUTES ANTIMICROBIAL SUSCEPTIBILITY TESTING, BY REGION, 2017–2028 REVENUE (USD MILLION)
18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
19. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
20. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
21. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
22. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
23. U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
24. U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
25. U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
26. U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
27. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
28. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
29. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
30. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
31. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
32. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
33. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
34. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
35. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
36. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
37. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
38. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
39. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
40. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
41. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
42. GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
43. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
44. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
45. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
46. FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
47. U.K. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
48. U.K. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
49. U.K. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
50. U.K. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
51. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
52. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
53. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
54. ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
55. SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
56. SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
57. SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
58. SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
59. SWEDEN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
60. SWEDEN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
61. SWEDEN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
62. SWEDEN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
63. BELGIUM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
64. BELGIUM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
65. BELGIUM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
66. BELGIUM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
67. TURKEY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
68. TURKEY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
69. TURKEY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
70. TURKEY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
71. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
72. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
73. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
74. RUSSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
75. POLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
76. POLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
77. POLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
78. POLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
79. SWITZERLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
80. SWITZERLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
81. SWITZERLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
82. SWITZERLAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
83. NETHERLANDS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
84. NETHERLANDS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
85. NETHERLANDS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
86. NETHERLANDS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
87. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
88. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
89. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
90. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
91. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
92. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
93. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
94. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
95. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
96. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
97. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
98. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
99. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
100. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
101. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
102. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
103. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
104. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
105. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
106. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
107. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
108. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
109. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
110. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
111. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
112. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
113. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
114. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
115. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
116. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
117. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
118. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
119. NEW ZEALAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
120. NEW ZEALAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
121. NEW ZEALAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
122. NEW ZEALAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
123. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
124. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
125. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
126. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
127. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
128. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
129. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
130. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
131. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
132. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
133. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
134. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
135. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
136. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
137. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
138. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
139. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
140. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
141. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
142. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
143. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
144. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
145. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
146. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
147. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
148. CHILE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
149. CHILE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
150. CHILE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
151. CHILE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
152. COLOMBIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
153. COLOMBIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
154. COLOMBIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
155. COLOMBIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
156. MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
157. MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
158. MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
159. MIDDLE EAST AND AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
160. UAE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
161. UAE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
162. UAE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
163. UAE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
164. SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
165. SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
166. SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
167. SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
168. SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
169. SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
170. SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
171. SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)
172. REST OF MEAANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2017–2028 REVENUE (USD MILLION)
173. REST OF MEAANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
174. REST OF MEAANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2017–2028 REVENUE (USD MILLION)
175. REST OF MEAANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END-USE, 2017–2028 REVENUE (USD MILLION)

LIST OF FIGURE
1. RESEARCH DESIGN
2. SCOPE OF THE STUDY
3. GEOGRAPHIC SCOPE
4. CURRENCY CONSIDERATION
5. YEAR CONSIDERATION
6. MARKET ESTIMATION
7. RESEARCH METHODOLOGY
8. DATA TRIANGULATION
9. COVID-19 IMPACT ON MARKET
10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY TYPE
11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY PRODUCT
13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY END-USE
14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY REGION
15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DYNAMICS
17. PESTEL ANALYSIS
18. SWOT ANALYSIS
19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY REGION
20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY TYPE
21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY APPLICATION
22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY PRODUCT
23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY END-USE
24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY NORTH AMERICA
25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY EUROPE
26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY ASIA PACIFIC
27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY SOUTH AMERICA
28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS BY MIDDLE EAST & AFRICA
29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)
30. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)
31. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)
32. ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)
33. SOUTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)
34. MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE BY COMPANY (2020)